Dr. Shu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 S. Greene St.
Baltimore, MD 21201Phone+1 410-328-7609Fax+1 410-328-6896
Education & Training
- Johns Hopkins UniversityFellowship, Medical Oncology, 2020 - 2024
- Johns Hopkins UniversityResidency, Internal Medicine, 2018 - 2020
- Johns Hopkins UniversityInternship, Internal Medicine, 2017 - 2018
- Lewis Katz School of Medicine at Temple UniversityClass of 2017
Certifications & Licensure
- MD State Medical License 2020 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 7 citationsSalvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.Stephanie L Alden, Mir Lim, Chester Kao, Daniel Shu, Amit G Singal
Cancer Research Communications. 2023-07-01 - 17 citationsProfiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments.Daniel J Zabransky, Ludmila Danilova, James M Leatherman, Tamara Y Lopez-Vidal, Jessica Sanchez
Hepatology. 2023-05-01 - 1 citationsImmunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma.Daniel H Shu, Won Jin Ho, Luciane T Kagohara, Alexander Girgis, Sarah M Shin
Nature Immunology. 2024-11-01
Press Mentions
- Lymph Node-like Structures May Trigger the Demise of Cancer TumoursOctober 30th, 2024
- Tertiary Lymphoid Structures Linked to Improved Treatment Outcomes in Liver CancerOctober 28th, 2024
- Lymph Node-like Structures May Trigger the Demise of Cancer TumorsOctober 25th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: